Trevi Therapeutics (TRVI) Stock Price, News & Analysis

Company Overview

Trevi Therapeutics (NASDAQ:TRVI) is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for metabolic and neurobehavioral disorders. The company’s research focuses on modulating neural circuits that regulate energy balance, glucose homeostasis and appetite control. Trevi’s pipeline includes small-molecule candidates designed to target specific receptors in the central nervous system, aiming to provide safer and more effective treatment options for conditions such as obesity, metabolic syndrome and related complications.

Among its lead programs, Trevi is advancing compounds through Phase 1 and Phase 2 clinical trials, evaluating safety, tolerability and preliminary efficacy in humans. These investigations are complemented by robust preclinical research that leverages both in vitro and in vivo models to optimize dose selection and refine pharmacological profiles. The company employs cutting-edge biomarker strategies to monitor drug activity and patient response, with the goal of accelerating clinical development and regulatory review.

Founded in 2018, Trevi Therapeutics operates headquarters in the United States with a research facility that supports drug discovery, preclinical testing and early clinical study management. The company collaborates with leading academic institutions and contract research organizations (CROs) to enhance its scientific capabilities and broaden access to specialized expertise. By combining internal expertise with strategic partnerships, Trevi seeks to streamline the path from laboratory innovation to potential market approval.

Trevi’s executive leadership team is composed of seasoned industry professionals with extensive experience across biotechnology, pharmacology and clinical development. The management group has a track record of advancing novel compounds through regulatory processes and commercial launches, positioning the company to address significant unmet medical needs. As Trevi Therapeutics continues to expand its clinical programs and international footprint, it aims to deliver transformative therapies that improve patient outcomes in metabolic and neurobehavioral health.

Key Stats

• Today's Range: $6.69 to $7.03
• 50-Day Range: $5.47 to $7.06
• 52-Week Range: $2.36 to $7.48
• Volume: 1.58 million shs
• Average Volume: 1.47 million shs
• Market Capitalization: $802.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.88
• Consensus Rating: Buy

Trevi Therapeutics Stock Analysis - MarketRank™

Trevi Therapeutics scored higher than 78% of companies evaluated by MarketBeat, and ranked 238th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.7 / 5
• Analyst Rating: Buy

Consensus Rating

Trevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.30, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Trevi Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.49) to ($0.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Trevi Therapeutics is -15.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Trevi Therapeutics is -15.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Trevi Therapeutics has a P/B Ratio of 5.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.16% of the float of Trevi Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Trevi Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Trevi Therapeutics has recently decreased by 97.98%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Trevi Therapeutics does not currently pay a dividend.

Dividend Growth

Trevi Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.16% of the float of Trevi Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Trevi Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Trevi Therapeutics has recently decreased by 97.98%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

Trevi Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

Search Interest

Only 9 people have searched for TRVI on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.

MarketBeat Follows

11 people have added Trevi Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 267% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Trevi Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.30% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.76% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TRVI Stock Analysis - Frequently Asked Questions

How have TRVI shares performed this year?

Trevi Therapeutics' stock was trading at $4.12 at the start of the year. Since then, TRVI shares have increased by 66.0% and is now trading at $6.84.

How were Trevi Therapeutics' earnings last quarter?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) posted its quarterly earnings data on Tuesday, May, 6th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.04.
Read the conference call transcript.

When did Trevi Therapeutics IPO?

Trevi Therapeutics (TRVI) raised $70 million in an initial public offering (IPO) on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets served as the underwriters for the IPO and Needham & Company was co-manager.

Who are Trevi Therapeutics' major shareholders?

Top institutional investors of Trevi Therapeutics include Diversified Trust Co (0.02%) and Farther Finance Advisors LLC (0.01%). Insiders that own company stock include David P Meeker, Thomas Sciascia, Jennifer L Good, Farrell Simon and Lisa Delfini.
View institutional ownership trends.

How do I buy shares of Trevi Therapeutics?

Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Trevi Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Trevi Therapeutics investors own include JPMorgan Chase & Co. (JPM), Predictive Oncology (POAI), Ford Motor (F), Tesla (TSLA), Meta Platforms (META), Abbott Laboratories (ABT) and Bank of America (BAC).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/17/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TRVI
• CIK: 1563880
• Web: www.trevitherapeutics.com
• Phone: (203) 304-2499
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Trevi Therapeutics: $20.88
• High Price Target: $29.00
• Low Price Target: $7.00
• Potential Upside/Downside: +205.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.30
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$47.91 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -58.41%
• Return on Assets: -52.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.38
• Quick Ratio: 15.38

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.30 per share
• Price / Book: 5.26

Miscellaneous

• Outstanding Shares: 117,290,000
• Free Float: 95,828,000
• Market Cap: $802.26 million
• Optionable: Optionable
• Beta: 0.46